Chapter 311 - 220: Groundbreaking Ceremony for the Liver Tumor Building

Chapter 311: Chapter 220: Groundbreaking Ceremony for the Liver Tumor Building

From this perspective, Jin Pharmaceutical Group had won a stunning victory. Pfizer could no longer halt the rise of this domestic pharmaceutical company.

Xu Changqing was a professional stock trader.

For the past few days, he had been tracking and researching a new stock: Jin Pharmaceutical Group.

He considered the recent news: Pfizer’s press conference, the impending launch of Jin Pharmaceutical Group’s new drug, and the enthusiastic public support it had received.

Xu Changqing quickly made his decision: buy Jin Pharmaceutical Group stock immediately!

And just as Xu Changqing had predicted, Jin Pharmaceutical Group’s stock price climbed steadily over the next few days.

The entire company was thriving!

The sanctions from Pfizer had backfired, only making the domestic enterprise more resilient.

Of course, everyone understood that "supporting a domestic enterprise" was just a superficial reason. The real deciding factor was Jin Pharmaceutical Group’s upcoming new drug: the Yangzheng Xiujie Pill.

The launch of this new drug—the first original, traditional Chinese medicine developed in Jin Province for treating primary liver cancer—signified a substantial market share, widespread market recognition, and a foreseeable, endless stream of profits!

At the same time, numerous investment firms flocked to Jin Pharmaceutical Group.

Even Jin Yihong hadn’t expected the new drug to bring such an immense fortune before it had even entered production.

Jin Yihong had already been looking for financing opportunities to increase R&D funding for Lou Musaang’s Banzhe Project.

This was the perfect opportunity. She initiated an equity financing plan, which, given the market’s high expectations, proceeded very smoothly.

Through this equity financing, Jin Yihong secured three billion in capital.

One-third of it was invested in subsequent production capacity for the Yangzheng Xiujie Pill, including building new factories, purchasing equipment and facilities, and procuring materials.

The remaining two billion was poured entirely into the R&D of the Banzhe Project. The plan was to quickly expand the research team, acquire more equipment, and purchase more advanced instruments. In short, Jin Pharmaceutical Group had entered an unprecedented state of aggressive "euphoria."

Fueled by all the positive news, the stock price continued to soar, and morale throughout Jin Pharmaceutical Group was sky-high.

Jin Yihong also traveled to the capital alone to meet with the director of the National Medical Products Administration.

She was running herself ragged for the new drug’s registration. As long as she could get it approved and move into production and market launch, this aggressive strategy of Jin Pharmaceutical Group’s would have a solid foundation.

Once the Yangzheng Xiujie Pill was in mass production, capturing the market, and sales revenue started flowing back in, everything would be on the right track.

For this trip to Qinghe City, Jin Yihong brought a complete set of clinical trial data and a summary of clinical research sufficient to prove the drug’s safety and efficacy. She was there to file for registration and apply for production and marketing approval.

Pfizer Jin Country Research Center, Xianglin City.

Xie Bin had just returned from the Southern Country.

He and Xu Kunlin were putting the final pieces of their plan into place.

"President Xie, the clinical trial data and the research summary on the drug’s safety and efficacy that we submitted have been approved!"

Xu Kunlin was truly first-rate when it came to falsifying data; the forgery was completely undetectable.

Xie Bin immediately contacted Richard, the acting director of the Office of Oncologic Diseases at the Southern Country FDA’s Center for Drug Evaluation and Research. They had long been in collusion, and the necessary bribes had already been paid.

"It looks like our new drug, Sorafenib, is on the verge of getting FDA approval."

"This time, to ensure we get certified before Jin Pharmaceutical Group’s Yangzheng Xiujie Pill, I had Richard put our new drug on the fast track."

Xie Bin was very smug. When it came to power plays and taking shortcuts, he was a grandmaster.

"This time, our new drug’s rapid market approval will benefit from three preferential policies: Accelerated Approval, the Breakthrough Therapy designation, and a primary liver cancer (malignant tumor) certification..."

Listening to Xie Bin’s masterfully calculated, step-by-step plan, Xu Linjun couldn’t help but feel a chill. ’This President Xie is terrifying... and absolutely ruthless.’

Crucially, he was an incredibly well-connected man, with a network that spread far and wide.

He had moles not only in the Southern Country FDA but also in Jin Country’s own National Medical Products Administration. This allowed him to monitor Jin Pharmaceutical Group’s every move at all times.

Xie Bin calmly continued to watch Jin Pharmaceutical Group’s latest developments.

"The old saying, ’to catch something, one must first let it go; to take, one must first give,’ is truly profound."

Xu Kunlin, standing by his side, praised him tremulously:

"President Xie, your foresight is truly godlike. Under our manipulation, Jin Pharmaceutical Group’s stock has skyrocketed. They’re already making preparations to start production of the Yangzheng Xiujie Pill, even though it hasn’t been approved yet... We also guided Jin Yihong into accelerating the R&D for the Banzhe Project. She’s undertaken aggressive equity financing and has poured nearly all of her cash flow into those two projects."

"And according to your plan, by investing in various traditional Chinese medicine suppliers and acquisition companies in the province, we’ve essentially cornered the market. We can now drive up the cost of several core ingredients for their Yangzheng Xiujie Pill, like Yinchen, on short notice."

"Now, everything is in place. We just have to wait for Jin Yihong to announce the launch of her new drug and begin mass production. Then, we can launch Sorafenib and strike her head-on..."